Estoque tril nasdaq

Trillium Therapeutics Inc. Common Shares (TRIL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Trillium Therapeutics Inc. Common Shares (TRIL) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Trillium Therapeutics Inc. Common Shares (TRIL) News Headlines | Nasdaq Health Care Sector Update for 03/20/2018: CRME, KMPH, AFMD, TRIL, MDT.

07/11/2019 · Trillium Therapeutics (NASDAQ:TRIL) Price Target and Consensus Rating. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. View Trillium Therapeutics Inc. TRIL investment & stock information. Get the latest Trillium Therapeutics Inc. TRIL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. 13/11/2019 · Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the nine months ended September … A sector Healthcare based Trillium Therapeutics Inc., (NASDAQ: TRIL) company closed its business at $0.48, by making the trend of 25.69% and showed a change of 50% from opening on 12-12-2019 (Thursday). Earnings-per-Share (EPS): EPS tells us, how much money the company is making in earnings per every-outstanding share of stock. View the latest Trillium Therapeutics Inc. (TRIL) stock price, news, historical charts, analyst ratings and financial information from WSJ. Access Google Drive with a free Google account (for personal use) or G Suite account (for business use). Analyzing Trillium Therapeutics (TSE:TRIL) stock? View TRIL's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat.

11/01/2020 · Trillium Therapeutics Inc. (NASDAQ:TRIL): Are Hedge Funds Right About This Stock? Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.

Access Google Drive with a free Google account (for personal use) or G Suite account (for business use). Analyzing Trillium Therapeutics (TSE:TRIL) stock? View TRIL's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat. 11/01/2020 · Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the nine months ended September … 16/04/2019 · Dados de preços históricos Trillium Therapeutics e gráficos TRIL. Cotações em tempo-real grátis, negócios e chat. Trillium Therapeutics (TRIL) preço da ação, gráfico, book, notícias; O fórum mais popular do Brasil. 22/12/2019 · Trillium Therapeutics Inc. (NASDAQ:TRIL) investors should be aware of an increase in hedge fund sentiment lately. TRIL was in 4 hedge funds' portfolios at the end of September. There were 3 hedge funds in our database with TRIL holdings at the end of the previous quarter. Our calculations also showed that TRIL isn't among the 30 most popular Trillium Therapeutics Inc. (NASDAQ:TRIL) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.

Stock quote for Trillium Therapeutics Inc. Common Shares Common Stock (TRIL) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq.

13/11/2019 · Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the nine months ended September … A sector Healthcare based Trillium Therapeutics Inc., (NASDAQ: TRIL) company closed its business at $0.48, by making the trend of 25.69% and showed a change of 50% from opening on 12-12-2019 (Thursday). Earnings-per-Share (EPS): EPS tells us, how much money the company is making in earnings per every-outstanding share of stock. View the latest Trillium Therapeutics Inc. (TRIL) stock price, news, historical charts, analyst ratings and financial information from WSJ. Access Google Drive with a free Google account (for personal use) or G Suite account (for business use). Analyzing Trillium Therapeutics (TSE:TRIL) stock? View TRIL's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat. 11/01/2020 · Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the nine months ended September …

Trillium Therapeutics historical price data and TRIL charts. Free real-time prices, trades, and chat. Trillium Therapeutics (TRIL) stock price, charts, trades & the US's most popular discussion forums.

TRIL did a great job of executing over the past few months in my opinion. It was enough to not only fill the previous gap but also get back to levels it was at prior to the big sell-off. Expand your Outlook. We've developed a suite of premium Outlook features for people with advanced email and calendar needs. An Office 365 subscription offers an ad-free interface, custom domains, enhanced security options, the full desktop version of Office, and 1 TB of cloud storage. Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC. ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Get breaking news and analysis on Trillium Therapeutics Inc. (TRIL) stock, price quote and chart, trading and investing tools. Stock analysis for Trillium Therapeutics Inc (TRIL:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Trillium Therapeutics Inc. Common Shares (TRIL) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.

02/01/2020 · Trillium Therapeutics Inc. Common Shares (TRIL) Latest Real Time Trades Data is currently not available. Select time If you do not opt-in you will not receive any emails from Nasdaq. Yes! I would like to receive Nasdaq communications related to Products, Industry News and Events. Trillium Therapeutics Inc (NASDAQ:TRIL) announced its earnings results on Thursday, November, 14th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.33) by $0.07. 24/12/2019 · Find the latest Institutional Holdings data for Trillium Therapeutics Inc. Common Shares (TRIL) at Nasdaq.com. Site uses Cookies. This website utilizes cookies and similar technologies for functionality and other purposes including personalization of content. Your use of this website constitutes your acceptance of cookies. To learn

24/12/2019 · Find the latest Institutional Holdings data for Trillium Therapeutics Inc. Common Shares (TRIL) at Nasdaq.com. Site uses Cookies. This website utilizes cookies and similar technologies for functionality and other purposes including personalization of content. Your use of this website constitutes your acceptance of cookies. To learn Income Statement for Trillium Therapeutics Inc. (TRIL) - view income statements, balance sheet, cash flow, and key financial ratios for Trillium Therapeutics Inc. and all the companies you research at NASDAQ… Please note that once you make your selection, it will apply to all future visits to NASDAQ.com. If, at any time, you are interested in reverting to our default settings, please select Default Setting above. If you have any questions or encounter any issues in changing your default settings, please email isfeedback@nasdaq.com. Shares of Trillium Therapeutics Inc. nearly doubled in very active trading Thursday, after the developer of cancer treatments provided an upbeat update on its TTI-621 and TTI-622 programs. The stock shot up 93% in afternoon trading, toward the highest close since Nov. 30. 12/01/2020 · Shares of Trillium Therapeutics Inc. nearly doubled in very active trading Thursday, after the developer of cancer treatments provided an upbeat update on its TTI-621 and TTI-622 programs. The stock shot up 93% in afternoon trading, toward the highest close since Nov. 30. Trading volume spiked to 46